73.26
전일 마감가:
$74.23
열려 있는:
$74.24
하루 거래량:
776.36K
Relative Volume:
0.70
시가총액:
$3.44B
수익:
-
순이익/손실:
$-38.99M
주가수익비율:
-24.45
EPS:
-2.9966
순현금흐름:
$-24.94M
1주 성능:
+4.69%
1개월 성능:
+46.37%
6개월 성능:
+33.39%
1년 성능:
+96.20%
Soleno Therapeutics Inc Stock (SLNO) Company Profile
명칭
Soleno Therapeutics Inc
전화
650-213-8444
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
SLNO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SLNO
Soleno Therapeutics Inc
|
73.26 | 3.44B | 0 | -38.99M | -24.94M | -2.9966 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-05 | 재개 | Stifel | Buy |
2024-12-02 | 재확인 | Robert W. Baird | Outperform |
2024-12-02 | 재확인 | Stifel | Buy |
2024-09-03 | 개시 | H.C. Wainwright | Buy |
2024-05-10 | 개시 | Robert W. Baird | Outperform |
2024-02-05 | 개시 | Piper Sandler | Overweight |
2024-01-23 | 개시 | Stifel | Buy |
2023-11-21 | 재개 | Guggenheim | Buy |
2020-09-29 | 개시 | Guggenheim | Buy |
2020-01-10 | 개시 | Craig Hallum | Buy |
2019-12-23 | 개시 | Oppenheimer | Outperform |
2018-02-13 | 재확인 | Maxim Group | Buy |
모두보기
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
Piper Sandler raises Soleno Therapeutics stock target to $145 By Investing.com - Investing.com Nigeria
Soleno Therapeutics (SLNO) Price Target Boosted to $145 by Piper Sandler | SLNO Stock News - GuruFocus
Capnia Inc stock soars to 52-week high, hits $74.11 By Investing.com - Investing.com India
Capnia Inc stock soars to 52-week high, hits $74.11 - Investing.com Australia
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET - The Manila Times
Soleno Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Soleno Therapeutics Launches First-Ever Earnings Call: Key Details for Q1 2025 Financial Results - Stock Titan
How To Trade (SLNO) - news.stocktradersdaily.com
Soleno Therapeutics appoints CBIZ CPAs as new auditor By Investing.com - Investing.com Nigeria
Soleno Therapeutics appoints CBIZ CPAs as new auditor - Investing.com Australia
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Geode Capital Management LLC - Defense World
Franklin Resources Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno launches Vykat xr for hyperphagia in Prader-Willi syndrome (SLNO:NASDAQ) - Seeking Alpha
Soleno Therapeutics launches FDA-approved PWS treatment By Investing.com - Investing.com South Africa
Soleno Launches Pill For Hyperphagia In Prader-Willi Syndrome Patients But Retail’s Unmoved - MSN
Soleno Therapeutics launches FDA-approved PWS treatment - Investing.com
Soleno Therapeutics Announces VYKAT(TM) XR Launch - The Manila Times
Breakthrough PWS Treatment VYKAT XR Now Available: First-Ever FDA Approval for Rare Disease - Stock Titan
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - MSN
KLP Kapitalforvaltning AS Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics (SLNO) Gains FDA Approval for Prader-Willi T - GuruFocus
SLNO Quantitative Stock Analysis - Nasdaq
Capnia Inc stock soars to 52-week high, hits $74 mark - Investing.com
Soleno therapeutics SVP sells $265,156 in stock By Investing.com - Investing.com India
Soleno therapeutics SVP sells $265,156 in stock - Investing.com
Soleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Bhatnagar Anish Sells 699,095 Shares - MarketBeat
Piper Sandler maintains $93 target on Soleno stock post-VYKAT XR nod By Investing.com - Investing.com South Africa
Piper Sandler maintains $93 target on Soleno stock post-VYKAT XR nod - Investing.com
High Growth Tech Stocks To Watch In The US April 2025 - simplywall.st
Soleno Therapeutics CEO sells $35.3 million in stock By Investing.com - Investing.com Philippines
Soleno Therapeutics CEO sells $35.3 million in stock - Investing.com Australia
Soleno Therapeutics CEO Anish Bhatnagar sells $35.3m in stock - Investing.com Australia
Soleno Therapeutics CEO Anish Bhatnagar sells $35.3m in stock By Investing.com - Investing.com Nigeria
Soleno Therapeutics exec sells shares worth $9.5 million By Investing.com - Investing.com South Africa
Soleno therapeutics director Matthew Pauls sells $424,797 in stock By Investing.com - Investing.com Canada
Soleno therapeutics’ SVP Yen Kristen sells $4.88 million in stock - Investing.com India
Soleno therapeutics director Matthew Pauls sells $424,797 in stock - Investing.com Australia
Soleno Therapeutics exec sells $700,330 in stock - Investing.com India
Soleno Therapeutics CFO sells $4.88 million in stock - Investing.com Australia
Soleno Therapeutics Executives and Director Sell Shares - TradingView
Soleno Therapeutics CCO sells shares worth $2.48m - Investing.com
Soleno therapeutics’ SVP Yen Kristen sells $4.88 million in stock By Investing.com - Investing.com UK
Soleno Therapeutics CCO sells shares worth $2.48m By Investing.com - Investing.com UK
Soleno Therapeutics CFO sells $4.88 million in stock By Investing.com - Investing.com UK
Soleno Therapeutics Executives Sell Shares - TradingView
Soleno Therapeutics exec sells shares worth $9.5 million - Investing.com
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock - Investing.com Australia
Soleno Therapeutics Inc (SLNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):